The effect of scalp electroacupuncture combined with Memantine in patients with vascular dementia

A retrospective study

Aixia Yue, MD, Xiuxing Han, MD, Enxia Mao, MMed, Guangling Wu, MMed, Junxiang Gao, MD, Liping Huang, PhD, Bin Zhou, MD

Abstract
Currently there is no effective treatment for vascular dementia (VaD). Pharmacological treatment often lead to severe complications and require drug dosage adjustment. This study investigated the effect of scalp electroacupuncture combined with Memantine in VaD. The safety and antioxidative effect of scalp electroacupuncture were also explored.

A retrospective study was conducted and data of inpatients of Linyi Central Hospital with VaD between June 2017 and May 2018 were collected and sorted. The patients were divided into scalp electroacupuncture-medication (A), scalp electroacupuncture (B) and medication (control) (C) groups, in which Memantine was prescribed as medication. Cognitive function, activities of daily living and quality of life assessed by Montreal Cognitive Assessment (MoCA), Barthel index and dementia quality of life questionnaire; the contents of superoxide dismutase, lipid peroxide and nitric oxide in blood samples; and adverse reaction were compared.

Data from a total of 150 patients were collected (Group A, n = 55; Group B, n = 50; Group C, n = 45). The post-treatment/follow-up Montreal Cognitive Assessment, Barthel index and dementia quality of life questionnaire scores were significantly improved in all groups compared to pre-treatment (groups A and B, P < .01; group C, P < .05). The improvements were significant for groups A vs C, B vs C (P < .01, both), and group A vs B (P < .01). The post-treatment/follow-up levels of lipid peroxide and nitric oxide decreased significantly while superoxide dismutase increased significantly in groups A and B compared to pre-treatment (P < .01, both). The differences were significant for groups A vs C, and B vs C (P < .01, both), but not significant between groups A and B (P > .05). There were no significant adverse events occurred during the study and follow-up.

In combined treatment, scalp electroacupuncture works in parallel with Memantine and significantly increase the therapeutic effect in VaD with no significant adverse events. Scalp electroacupuncture may have the potential to serve as an option or alternative treatment for VaD. Scalp electroacupuncture may alleviate VaD symptoms through its antioxidative mechanism.

Abbreviations: AD = Alzheimer’s disease, ANOVA = analysis of variance, BI = Barthel index, CDR = clinical dementia rating, DEMQOL = dementia quality of life questionnaire, LPO = lipid peroxide, MoCA = Montreal Cognitive Assessment, NO = nitric oxide, ROS = reactive oxygen species, SOD = superoxide dismutase, VaD = vascular dementia.

Keywords: memantine, scalp electroacupuncture, vascular dementia
1. Introduction

Vascular dementia (VaD) is the second most common type of dementia after Alzheimer’s disease (AD), accounting for 15% to 20% of all cases. Unlike AD, there are currently no licensed treatments for VaD, and its mean survival rate is lower than AD. VaD is characterized by cognitive impairment and cerebrovascular pathologies caused by brain damage due to impaired blood flow over a long period of time. VaD and cerebrovascular diseases have the common risk factors, including hypertension, diabetes, obesity, and hyperlipidemia. Other risk factors for VaD are aging, atherosclerosis and stroke.

Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species (ROS) and the biological system ability to readily detoxify the reactive intermediates. It has been demonstrated to involve in the pathogenesis of AD and VaD. Researches have been conducted to investigate if antioxidant therapy exerts a role in the prevention and treatment of these diseases. Previous researches have also highlighted the importance of oxidative stress in both normal and pathological brain aging. Oxidative stress is not only linked to VaD, but also to all its risk factors.

The current treatment for VaD such as antioxidants, anti-inflammatory agents or agents increasing cerebral perfusion have not yield satisfactory results. Pharmacological treatment often lead to severe complications due to hypersensitivity of the brain in patients with dementia and decrease of hepatic and kidney drug metabolism with advance age. The drug dosage often requires regular adjustment. Early evidence suggests that multifactorial interventions may prevent or delay the onset of dementia.

Acupuncture is often used as a treatment for dementia. It can relieve VaD symptoms with minimal side effects, improve cognitive and emotional capabilities, and reduce VaD severity. Electroacupuncture reduces functional deficits of neuropathy, prevents cognitive deficiency, and significantly improves learning and memory capacity. Scalp acupuncture stimulates the lesion area on the scalp to produce therapeutic effects. Its efficacy for VaD has been confirmed by numerous empirical clinical studies. It can also improve the clinical intelligence level of VaD patients.

Studies have shown that the cognitive enhancing effect of acupuncture is likely to be at least partially attributable to decreased oxidative stress. Liu et al. found that acupuncture could improve memory impairment through increasing antioxidant system ability in hippocampus of VaD rats. Experimental studies reported that electroacupuncture could effectively attenuate lipid peroxidation content through increasing antioxidant enzyme activities such as superoxide dismutase (SOD) in hippocampal CA1 of VaD rats. Previous study found that inducible nitric oxide (NO) synthase expression and NO production in glial cells can cause NO diffusion and neurotoxicity which exacerbate delayed infarct expansion and play a key pathological role in ischemic injury. Increasing evidences suggested that the neurotoxic effects of inducible NO synthase derived NO could aggravate cerebral ischemia/reperfusion injury, while electroacupuncture could provide neuroprotection against delayed infarct expansion and subsequently reduce oxidative stress in cerebral ischemia/reperfusion injury. These observations suggested that acupuncture may alleviate VaD symptoms through its antioxidative mechanism.

Memantine is a moderate-affinity, uncompetitive NMDA receptor antagonist that has been shown to have therapeutic potential in numerous central nervous system disorders without undesirable side effects. It has been shown to prevent neurodegeneration and learning deficits in animal models of dementia, and reduce neuronal damage in global and focal animals models of brain ischemia. Previous study revealed significant neuroprotective activity against oxidative stress from antioxidant properties of Memantine derivatives.

In this study, we compared the effect of scalp electroacupuncture combined with Memantine, scalp electroacupuncture and Memantine in patients with VaD. Safety evaluation was performed, and the antioxidative effect of scalp electroacupuncture in VaD treatment was explored. We hypothesized that combination with scalp acupuncture would increase the therapeutic effect of Memantine in VaD treatment. The findings of the present study may help to provide more clinical evidence to develop a novel therapeutic approach for VaD.

2. Materials and methods

2.1. Patients

A retrospective review was performed and data for all inpatients of Linyi Central Hospital diagnosed with VaD between June 2017 and May 2018 were collected and sorted. The patients who met the criteria for probable VaD as defined by the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l’Enseignement en Neurosciences or diagnostic criteria for dementia in the Diagnostic and Statistical Manual of Mental Disorders (4th Edition). Inclusion criteria: symptoms of dementia; acute onset or a step-progressive duration of the illness; definite signs of dementia; mild (clinical dementia rating [CDR] = 1.0) or moderate (CDR = 2.0) CDR; Hachinski ischemia score ≥ 7; availability of a reliable caregiver. Exclusion criteria: prior diagnosis of AD, Parkinson disease, Huntington disease, or other neurodegenerative dementia; presence of abnormal executive control function; inability to give consent; severe neurological deficits; severe mental disorders. The details collected included baseline data (age, gender, duration of VaD, education, location of lesion, diagnosis, and comorbidities), therapeutic outcome (cognitive function, activities of daily living and quality of life assessed by Montreal Cognitive Assessment [MoCA], Barthel index [BI] and dementia quality of life questionnaire [DEMQOL], levels of SOD, lipid peroxide [LPO] and NO, and adverse events occurred. The data were sorted by 2 researchers independently and crosschecked. Any discrepancies would be discussed with a third researcher. This retrospective study was approved by the Ethics Committee of Linyi Central Hospital (No. LCN201704169) and the requirement for informed consent was waived.

2.2. Grouping

The participants were divided into: scalp electroacupuncture-medication group (A), scalp electroacupuncture group (B) and medication group (control) (C). Memantine 10mg twice daily was prescribed for medication.

2.3. Treatment and follow-up

The patients received a total course of 6-week treatment and a 4-week post-treatment follow-up. Evaluation were performed 4-week post-treatment follow-up. Evaluation were performed
after completed treatment and at the end of follow-up. They were allowed to continue medications for lowering blood pressure and cholesterol. The patients were contacted regularly by the staffs to remind them for subsequent visits, which helped to minimize drop-out rates.

2.4. Treatment procedure

The subjects in groups A and B received scalp electroacupuncture. Based on the results of previous studies,[48] the acupoints Sishencong (EX-HN 1), Baihui (GV 20), Shenting (GV 24) and (bilateral) Fengchi (GB 20) were applied for treatment. Disposable Chinese acupuncture stainless filiform needles (Hwato brand, Suzhou Medical Appliances Factory, Suzhou, Jiangsu, P.R. China) size 0.30 mm x 40 mm were used. All needles were sterilized with 75% alcohol before use. With the patient in sitting position, the area around the acupoints were disinfected with 75% alcohol. For Fengchi acupoint, the needles were punctured obliquely into a depth of 15 to 30 mm. For remaining acupoints, by forming an angle of 15°-30° with the scalp, the needles were penetrated obliquely into a depth of 15 to 25 mm. After deqi, the needles were connected to an electrical stimulator (Gene-805-2, Shanghai Huayi Medical Instrument Co., Ltd, Shanghai, P.R. China), continuous wave, frequency 3 to 15 Hz, and current intensity 2 to 4 mA (stimulation depended on patients tolerance). Shenting (GV 24), Baihui (GV 20), left and right Sishencong (EX-HN 1) formed a group of acupoints; anterior and posterior Sishencong (EX-HN 1), and left and right Fengchi (GB 20) formed a group of acupoints. Both groups were applied alternately. Shenting (GV 24) was connected to the positive electrode, left Sishencong (EX-HN 1) was connected to the negative electrode; Baihui (GV 20) was connected to the positive electrode, right Sishencong (EX-HN 1) was connected to the negative electrode; anterior Sishencong (EX-HN 1) was connected to the positive electrode, left Fengchi (GB 20) was connected to the negative electrode; posterior Sishencong (EX-HN 1) was connected to the positive electrode, right Fengchi (GB 20) was connected to the negative electrode. Each treatment lasted for 30 minute, once a day, 5 days per week, for 6 weeks.

All patients were treated by a licensed traditional Chinese medicine practitioner with over 15 years of experience. Participants in Groups A and C received Memantine (Bayer Healthcare Co., Ltd., Beijing, China) 10mg twice daily, for 6 weeks.

2.5. Observation of therapeutic efficacy

The MoCA, BI, and DEMQOL were measured within 24 hour of admission, after completed treatment and at the end of follow-up. The levels of SOD, LPO, and NO were also evaluated. 10 mL of venous blood was drawn from all patients after overnight fasting. Reagents and detection kits were purchased from Nanjing Jiancheng Bioengineering Institute Co., Ltd., Nanjing, Jiangsu, P. R. China. The evaluation was performed by assessors who were blinded with the type of treatment the patients received.

2.6. Safety event

Any adverse events were recorded and intervention would be stopped immediately. Acupuncture-related adverse events included cases of needle site bleeding, hemotoma, increase pain, fainting, and local infection. Vital signs (temperature, heart rate, blood pressure), and physical examination were performed during each visit.

2.7. Main outcome measures

The primary outcome measure was the therapeutic effect. The secondary outcome measure was safety evaluation, and the antioxidative effect.

2.8. Statistical analysis

Data were presented as mean±standard deviation for continuous variables or percentages for categorical variables. For baseline characteristics, enumeration data of each variable were compared with Chi-square test, while the measurement data were compared with analysis of variance (ANOVA) test. For evaluation of the therapeutic effect and antioxidative effect, nonparametric ANOVA (Kruskal-Wallis \( H \) test) followed by pairwise multiple comparisons were used to compare the pre-/post-treatment or pre-treatment/follow-up differences of the same group. Wilcoxon signed-rank test was used for comparisons with the control group. Statistical analysis was performed using SPSS software (version 19.0, SPSS, Chicago, Illinois) and \( R \) version 2.4.1. \( P < .05 \) was considered as statistically significant. The analyzes were performed on intention-to-treat basis, with missing data replaced by last observation carried forward. Intention-to-treat analysis evaluates treatment effects over the population with at least 1 post-treatment evaluation. The last observation carried forward ANOVA performs statistical test for treatment effects by treating the last observation prior to drop-out as the observation from the last visit.

3. Results

Data from a total of 150 subjects were collected. Group A, n = 55; Group B, n = 50; Group C, n = 45). There were 3 missing data, 1 from each group due to loss to follow-up.

3.1. Baseline characteristics

The 3 groups were comparable with regard to baseline characteristics (\( P > .05 \)) (Table 1). Figure 1 showed typical CT and MRI images of a patient with multi-infarct dementia.

3.2. Assessment

The post-treatment/follow-up MoCA, BI and DEMQOL scores were significantly improved in all groups compared to pre-treatment (groups A and B, \( P < .01 \); group C, \( P < .05 \)). The improvements were significantly different (group A vs C and group B vs C, \( P < .01 \); group A vs B, \( P < .05 \)) (Table 2 and Supplementary Table 1, http://links.lww.com/MD/E619).

3.3. Adverse events reporting

There were no acupuncture-related adverse events occurred during the study and follow-up.

3.4. Test indicators

The post-treatment/follow-up levels of LPO and NO decreased significantly while SOD increased significantly in groups A and B compared to pre-treatment (\( P < .01 \), both). The differences were significant for groups A vs C and B vs C (\( P < .01 \), both), but not significant between group A and B (\( P > .05 \)) (Table 3).
### Table 1
Baseline characteristics.

| Variable                      | Scalp electroacupuncture-medication (Group A, n = 55) | Scalp electroacupuncture (Group B, n = 50) | Medication (control) (Group C, n = 45) | P value |
|-------------------------------|------------------------------------------------------|-------------------------------------------|----------------------------------------|---------|
| Gender, n (%)                 |                                                      |                                           |                                        |         |
| Male                          | 41 (74.5)                                            | 38 (76.0)                                 | 34 (75.6)                              |         |
| Female                        | 14 (25.5)                                            | 12 (24.0)                                 | 11 (24.4)                              | .12     |
| Age (yr)                      | 66.1 ± 7.0                                           | 66.7 ± 7.5                                | 66.5 ± 7.2                             | .51     |
| Duration of VaD               |                                                      |                                           |                                        |         |
| ≤3 mo                         | 25 (45.4)                                            | 22 (44.0)                                 | 20 (44.4)                              |         |
| 3 mo - ≤1 yr                  | 12 (21.8)                                            | 11 (22.0)                                 | 10 (22.2)                              |         |
| 1-2 yr                        | 9 (16.4)                                             | 9 (18.0)                                  | 8 (17.8)                               |         |
| ≥2 yr                         | 9 (16.4)                                             | 8 (16.0)                                  | 7 (15.6)                               | .26     |
| Education (yr)                |                                                      |                                           |                                        |         |
| 0                             | 6 (11.0)                                             | 6 (12.0)                                  | 5 (11.1)                               | .33     |
| 1-6                           | 8 (14.5)                                             | 8 (16.0)                                  | 7 (15.6)                               |         |
| 7-9                           | 30 (54.5)                                            | 27 (54.0)                                 | 24 (53.3)                              |         |
| ≥10                           | 11 (20.0)                                            | 9 (18.0)                                  | 9 (20.0)                               |         |
| Location of lesion            |                                                      |                                           |                                        |         |
| Left-sided lesions            | 19 (34.6)                                            | 17 (34.0)                                 | 15 (33.3)                              |         |
| Right-sided lesions           | 23 (41.8)                                            | 21 (42.0)                                 | 19 (42.2)                              |         |
| Bilateral lesions             | 13 (23.6)                                            | 12 (24.0)                                 | 11 (24.5)                              | .19     |
| Diagnosis                     |                                                      |                                           |                                        |         |
| Infarct dementia              | 46 (83.6)                                            | 42 (84.0)                                 | 37 (82.2)                              |         |
| Multi infarct                 | 10                                                   | 10                                        | 8                                      |         |
| Strategic infarct             | 8                                                    | 7                                         | 7                                      |         |
| Small vessel                  | 28                                                   | 25                                        | 22                                     |         |
| Hemorrhagic dementia          | 4 (7.3)                                              | 3 (6.0)                                   | 3 (6.7)                                |         |
| Mixed dementia                | 5 (9.1)                                              | 5 (10.0)                                  | 5 (11.1)                               | .28     |
| Comorbidities                 |                                                      |                                           |                                        |         |
| Cardiological cardiovascular disease | 11 (20.0)                              | 9 (18.0)                                  | 8 (17.8)                               |         |
| Hypertension                  | 27 (49.1)                                            | 26 (50.0)                                 | 23 (51.1)                              |         |
| Vascular                      |                                                      |                                           |                                        |         |
| Atherosclerosis               | 7 (12.7)                                             | 7 (14.0)                                  | 8 (17.8)                               |         |
| Stroke                        | 7 (12.7)                                             | 6 (12.0)                                  | 6 (13.3)                               |         |
| Metabolic/Endocrine           |                                                      |                                           |                                        |         |
| Obesity                       | 6 (10.9)                                             | 8 (16.0)                                  | 5 (11.1)                               | .43     |
| Diabetes                      | 7 (12.7)                                             | 5 (10.0)                                  | 6 (13.3)                               |         |

Note: Data were presented as mean ± standard deviation or number of patients (n) with percentage (%). The P value indicated comparison among the 3 groups for each variable. The enumeration data were compared with Chi-square test, while the measurement data were compared with ANOVA test. Abbreviations: MoCA = Montreal Cognitive Assessment, BI = Barthel index, DEMQOL = dementia quality of life questionnaire.

![Figure 1](image)  
Figure 1. Typical (A) CT (B) MRI images of a patient with multi-infarct dementia. CT = computed tomography, MRI = magnetic resonance imaging.
The differences between groups A and C, and between groups B and C were significantly different for test indicators. As according to the results, the improvements were significant for groups A vs C and B vs C (P<.01), pre- and post-treatment/follow-up differences compared with group C. The differences between groups A and C, and between groups B and C were P<.01 for both, which were presented as †† in the table.

### 4. Discussion

Studies have shown higher incidence of VaD in men than in women.[5] Females are at greater risk of developing AD, while males are at greater risk of developing VaD.[49] Between 1% and 4% of people over 65 years suffer from VaD,[50] while the prevalence appears to double every 5 to 10 years.[51] Advanced age and gender are 2 of the most prominent risk factors for dementia.[49] Previous systematic review[52] found association between lower education with greater risk for dementia in many but not all studies. The level of education associated with risk for dementia varied by study population, and more years of education did not uniformly attenuate the risk for dementia. The definition of low education may ranged from illiterate to less than 15 years, but the highest education level may ranged from literate to 17+ years. Some studies divided education into categories and identified each level as significant or not significant. In this study, the mean education duration (year) for group A, group B and group C was 7.01±1.05, 7.12±1.13, and 7.06±1.08 respectively. If divided according to the number of years of education, the number of patients in the low education group (<10 years of education) was significantly higher than the high education (>10 years of education) (P<.05), and dividing into categories showed most patients received 7 to 9 years of education (P<.05, compared with other categories). It was suggested that the effect of education on risk for dementia may be best evaluated within the context of a lifespan developmental model.

Previous meta-analysis review indicated that acupuncture has neuroprotective, antioxidant and anti-apoptosis effect in VaD.[53] With the advance of new knowledge and technology, additional methods such as electroacupuncture and new acupuncture points are being developed.[14] Electropuncture substitutes for prolonged hand maneuvering and helps ensuring that the patient gets the amount of stimulation needed. It also reduces the total treatment time by providing continued stimulus. The frequency and amount of stimulus are easier to control than with manual acupuncture, and its immediate effect was superior to acupuncture in VaD patients. A meta-analysis study on VaD treatment with different acupuncture methods found good therapeutic effect with electroacupuncture.[55]

### Table 3

| Group | Total cases (n) | Pre-treatment | Post-treatment | Follow-up | Pre-treatment | Post-treatment | Follow-up | Pre-treatment | Post-treatment | Follow-up |
|-------|----------------|---------------|----------------|-----------|---------------|----------------|-----------|---------------|----------------|-----------|
| Scalp electroacupuncture- medication (Group A) | 55 | 50.21±1.21 | 58.17±1.35 | 58.89±1.38 | 50.21±1.21 | 58.17±1.35 | 58.89±1.38 | 50.21±1.21 | 58.17±1.35 | 58.89±1.38 |
| Scalp electroacupuncture (Group B) | 50 | 50.23±1.23 | 58.89±1.38 | 58.89±1.38 | 50.23±1.23 | 58.89±1.38 | 58.89±1.38 | 50.23±1.23 | 58.89±1.38 | 58.89±1.38 |
| Medication (control) (Group C) | 45 | 50.25±1.24 | 58.87±1.37 | 58.87±1.37 | 50.25±1.24 | 58.87±1.37 | 58.87±1.37 | 50.25±1.24 | 58.87±1.37 | 58.87±1.37 |

**Note:** Data were presented as mean±standard deviation, n: number of patients.

SOD = superoxide dismutase, LPO = lipid peroxide; NO = nitric oxide.

As according to the results, the differences for test indicators were significant for groups A vs C and B vs C (P<.01, both), and not significant between group A and B (P>0.05).

The differences between groups A and C, and between groups B and C were P<.01 for both, and were presented as †† in the table.
Scalp acupuncture is a modern innovation. Its intervention areas are based on the reflex somatotopic system organized on the scalp surface. The needles are subcutaneously inserted into various zones which are specific areas through which the central nervous system, endocrine system, and channels are transported to and fro. From a Western perspective, these zones are corresponded to the cerebrum and cerebellum areas responsible for motor activity, sensory, vision, speech, hearing, and equilibrium. Scalp acupuncture also helps to strengthen the immune system and prevent illness. It is less expensive, entails less risk, yield quicker responses, and causes fewer side effects than many pharmacological treatments. Its use as a main tool for rehabilitation is a relatively new concept.[14]

The results from this study shows that in group A, scalp electroacupuncture works in parallel with Memantine, and significantly improve the cognitive function, activities of daily living and quality of life in patients with VaD. The effect of scalp electroacupuncture alone (group B) is significantly stronger than Memantine (group C), suggesting the possibility of complete substitution of the medication with scalp electroacupuncture. Scalp electroacupuncture may have the potential to serve as an option or alternative treatment for VaD. Previous study reported low incidence of dizziness and constipation with Memantine in mild to moderate VaD. Despite this, overall it is well tolerated and safe.[55] Thus, combination with scalp electroacupuncture may reduce the dosage of the medication required to achieve similar therapeutic effect, and this may further reduce the risk of adverse events.

Baihui (GV 20), Sishencong (EX-HN 1), Shenting (GV 24) and Fengchi (SP 40) are among the frequently used acupoints in VaD treatment.[57] Baihui can decrease cerebral ischemic-reperfusion injury, and improve neurofunction.[58,59] Sishencong improves the quality of sleep.[60] Treatment at Baihui and Shenting can improve cognitive function.[61] Modern research shows that Baihui, Sishenchong and Shenting are located in the projection area of frontal, temporal and parietal lobes, which is closely related to human’s advanced thinking, memory and mind.[62] Treatment at Fengchi (GB 20) can directly improve brain function.[63]

SOD is the most crucial antioxidant enzyme.[64] It catalyzes the dismutation of superoxide anion free radical (O2•−) into molecular oxygen and hydrogen peroxide (H2O2), and decrease the O2− level which damages the cells at excessive concentration.[65] The decrease in SOD level indicates aging.[66] Studies have confirmed that ROS is an important cause of neuronal damage after cerebral hypoxia-ischemia.[67,68] LPO is a product of combination of the ROS and polyunsaturated fatty acids. Its significant increase causes serious damages to human cells, and to the structure and function of cell membrane.[69] LPO can also cause damage and fibrosis to the arterioles.[70] NO is a biological intercellular messenger or neurotransmitter.[71] It relaxes smooth muscle and inhibits platelet aggregation and cytotoxicity. NO derived from endothelial cells has anti-atherosclerotic effect and may be related to learning and memory.[7,2] Increase of NO has both protective and damaging effects.[73]

Previous systematic review suggested that acupuncture can improve cognitive function in animal studies[53,74] and increase cerebral blood flow.[75] Acupuncture treatment can significantly increase SOD activity in brain and reduce brain tissue damage caused by free radical in rats.[53,76] It was found that the outcome on memory consolidation was closely correlated with the change of LPO and SOD in the brain. Higher SOD activity, lower LPO content and elevated SOD/LPO ratio in the brain were presented in rats which did well in the water maze test, showing significant effect of acupuncture in antagonizing oxygen stress.[77,78] Previous studies suggested that electroacupuncture can reduce the extent of lipid peroxidation in brains of rats with ischemic-reperfusion injury,[79] decrease NO content[79] and enhance SOD activity.[75,79] The present study shows that scalp electroacupuncture significantly increases the activity of SOD and decrease LPO and NO, indicating that it may enhance the body’s ability to scavenge ROS and to oxidize, preventing it from causing further damage, and thus contribute to the patients recovery.

In this study, the continuation of increasing effect in the follow-up suggesting scalp electroacupuncture has persistent effect over the 4 weeks of post-treatment. The underlying mechanisms of scalp electroacupuncture on cognitive improvement may be partially attributable to its ability to enhance the body’s capability to scavenge ROS and promote balance, which may contribute to the prolonged sustained effects of scalp electroacupuncture. This may provide a new insight to explore the efficacy of its long term effects in future studies, and to develop a schedule if further treatment is required to reinforce the effect in long term control.

In conclusion, in combined treatment, scalp electroacupuncture works in parallel with Memantine and significantly increase the therapeutic effect in VaD with no significant adverse events. Scalp electroacupuncture may have the potential to serve as an option or alternative treatment for VaD. Scalp electroacupuncture may alleviate VaD symptoms through its antioxidative mechanism. The limitation of this study is it mainly focused on the short-term therapeutic effects. Further studies may involve comparisons with sham electroacupuncture. Future studies may evaluate the long-term therapeutic effects, as well as comparisons with other newer drug generation. In addition, the differences in outcome based on the site of lesions may also be explored.

Author contributions
Aixia Yue, Xiuxing Han and Bin Zhou designed the studies. Aixia Yue, Xiuxing Han, Enxia Mao, Guangling Wu, Junxiang Gao and Liping Huang performed the data collection and statistical analysis. Aixia Yue, Xiuxing Han, Enxia Mao and Bin Zhou conducted the data interpretation. Aixia Yue prepared the manuscript. Aixia Yue and Xiuxing Han did the literature search. All authors approved with the final manuscript.

References
[1] O’Brien JT, Thomas A. Vascular dementia. Lancet 2015;386:1698–706.
[2] Rustenberg A, Ott A, van Swieten JC, et al. Incidence of dementia: does gender make a difference? Neurobiol Aging 2001;22:575–80.
[3] Barclay LL, Zemcov A, Blass JP, et al. Survival in Alzheimer’s disease and vascular dementias. Neurology 1985;35:834–40.
[4] Gorelick PB, Sutker A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:2672–713.
[5] Iadecola C. The pathobiology of vascular dementia. Neuron 2013;80:844–66.
[6] Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 2009;66:300–5.
[7] Fillit H, Nash DT, Rundek T, et al. Cardiovascular risk factors and dementia. Am J Geriatr Pharmacother 2008;6:100–18.
[8] Honjo K, Black SE, Verheoef NP. Alzheimer’s disease, cerebrovascular disease, and the amyloid cascade. Can J Neurol Sci 2012;39:712–28.
[9] Farnell C, Gao S, Callahan CM, et al. Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Alzheimer Dis Assoc Disord 2009;23:1–0.

[10] Song J, Lee WT, Park KA, et al. Association between risk factors for vascular dementia and apolipoprotein. Biomed Res Int 2014;2014:261672 (page 1–13).

[11] Lasségue B, Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 2010;30:653–61.

[12] Luca M, Luca A, Calandra C. The role of oxidative damage in the pathogenesis and progression of Alzheimer’s disease and vascular dementia. Oxid Med Cell Longev 2015;2015:304678.

[13] Allan Butterfield D, Howard B, Yatin S, et al. Elevated oxidative stress in models of normal brain aging and Alzheimer’s disease. Life Sci 1999;65:1883–92.

[14] Rodríguez-Mansilla J, González-López-Arza MV, Varela-Donoso E, et al. Ear therapy and massage therapy in the elderly with dementia: a pilot study. J Tradit Chin Med 2013;33:461–7.

[15] Herrmann N, Gauthier S. Diagnosis and treatment of dementia. 6. Management of severe Alzheimer disease. CMAJ 2008;179:1279–87.

[16] Kim Y, Wilkins KM, Tampi RR. Use of gabapentin in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2011;82(9):910–2.

[17] Lin CC, Chen MC, Yu SN, et al. Chronic electrical stimulation of four acupuncture points on rat diabetic neuropathy. Conf Proc IEEE Eng Med Biol Soc 2005:661–6.

[18] Cheng HK. How can acupuncture be used in treating dementia? QJM Intern Complement Med 2018;1:1–28.

[19] Lee MS, Shin BC, Ernst E. Acupuncture for Alzheimer’s disease: a systematic review. Int J Clin Pract 2009;63:874–9.

[20] Yu J, Zhang X, Liu C, et al. Effect of acupuncture treatment on vascular dementia. Neurol Res 2006;28:97–103.

[21] Shi GX, Liu CZ, Guan W, et al. Effects of acupuncture on Chinese medicine syndromes of vascular dementia. Chin J Integr Med 2014;20:616–6.

[22] Lin CC, Chen MC, Yu SN, et al. Chronic electrical stimulation of four acupuncture points on rat diabetic neuropathy. Conf Proc IEEE Eng Med Biol Soc 2005:4:4271–4.

[23] Do Santos JG Jr, Tabosa A, do Monte FH, et al. Electroacupuncture prevents cognitive deficits in pilocarpine-epileptic rats. Neurosci Lett 2005;384:234–8.

[24] Jing XH, Chen SL, Shi H, et al. Electroacupuncture restores learning and memory impairment induced by both diabetes mellitus and cerebral ischemia in rats. Neurosci Lett 2008;441:193–8.

[25] You YN, Cho MR, Park JH, et al. Assessing the quality of reports about randomized controlled trials of scalp acupuncture treatment for vascular dementia. Trials 2017;18:205.

[26] Wang Y, Shen J, Wang XM, et al. Scalp acupuncture for acute ischemic stroke: a meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2012;2012:480950 (page 1–9).

[27] Lee GE, Park JH, Yang HD, et al. The current state of clinical studies on scalp acupuncture-treatment for dementia-by search for China literature published from 2001 to 2011 in CAJ (China Academic Journals). J Orient Neuropsychiatr 2012;23:13–32.

[28] Peng W, Zhao H, Liu Z, et al. Systematic assessment of electroacupuncture treatment for vascular dementia. Chin Acu-mox 2004;24:297–301.

[29] Liu YC, Zhang HX, Chen GH, et al. Therapeutic effects of scalp-acupuncture in patients with vascular dementia induced by cerebral infarction: a randomized controlled trial. J Chin Integr Med 2008;6:806–9.

[30] Jinwat J, Wattanathorn J. Ginger pharmacopuncture improves cognitive impairment and oxidative stress following cerebral ischemia. J Acupunct Meridian Stud 2012;5:295–300.

[31] Liu CZ, Yu JC, Zhang XZ, et al. Acupuncture prevents cognitive deficits and oxidative stress in cerebral multi-infarction rats. Neurosci Lett 2006;393:45–50.

[32] Liu CZ, Li ZG, Wang DJ, et al. Effect of acupuncture on hippocampal Ret-1 expression in cerebral multi-infarction rats. Neurol Sci 2013;34:205–12.

[33] Sui FK, Lo SC, Leung MC. Effectiveness of multiple pre-ischemia electroacupuncture on attenuating lipid peroxidation induced by cerebral ischemia in adult rats. Life Sci 2004;75:1323–32.

[34] Sui FK, Lo SC, Leung MC. Electroacupuncture reduces the extent of lipid peroxidation by increasing superoxide dismutase and glutathione peroxidase activities in ischemic-reperfused rat brains. Neurosci Lett 2004;34:158–62.

[35] Chiu XD, Ma YH, Luo P, et al. Up-regulation of heme oxygenase-1 attenuates brain damage after cerebral ischemia via simultaneous inhibition of superoxide production and preservation of NO bioavailability. Exp Neurol 2013;239:163–9.

[36] Wang YH, Wang WY, Chang CC, et al. Taxifolin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-oxidative effect and modulation of NF-kappa B activation. J Biomed Sci 2006;13:127–41.

[37] Cheng CY, Lin JG, Tang NY, et al. Electroacupuncture-like stimulation at the Baihui (GV20) and Dazhui (GV14) acupoints protects rats against subacute-phase cerebral ischemia-reperfusion injuries by reducing S100B-mediated neurotoxicity. PLoS One 2014;9:e91426.

[38] Parsons CG, Danyz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist—a review of preclinical data. Neuropharmacology 1999;38:735–67.

[39] Barnes CA, Danyz W, Parsons CG. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 1996;8:563–71.

[40] Zajaczkowski W, Quack G, Danyz W. Infusion of (+)-MK-801 and memantine: contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996;296:239–46.

[41] Heim C, Sontag KH. Memantine prevents progressive functional neurodegeneration in rats. J Neural Transm Suppl 1995;46:117–30.

[42] Frankiewicz T, Pirc A, Parsons CG. Differential effects of NMDA receptor antagonists on long-term potentiation and hypoxia/hypoglycaemic excitotoxicity in hippocampal slices. Neuropharmacology 2000;39:631–42.

[43] Fornasari E, Marmelli L, Di Stefano A, et al. Synthesis and antioxidant properties of novel Memantine derivatives. Cent Nerv Syst Agents Med Chem 2017;17:123–8.

[44] Roman GC, Tattemchi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1999;53:250–60.

[45] American Psychiatry AssociationDiagnostic and Statistical Manual of Mental Disorders. 4th ed.Washington, USA: American Psychiatric Publishing; 1994.

[46] Manning CA, Ducharme JK. Lichtenberg PA. Dementia syndromes in the older adult. Handbook of assessment in clinical gerontology 2nd ed.USA: Academic Press, Elsevier; 2010;155–78.

[47] Fu RJ. The diagnosis, type-differentiation and criteria of therapeutic effects for senile dementia (a discussion manuscript). J Tradit Chin Med 1991;2:56.

[48] Zhang H, Zhu WJ, Yang YL. Evidence-based medical evaluation of common therapies of acupuncture and moxibustion for vascular dementia. Chin J Clin Rehabil 2005;9:173.

[49] Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementia. Dialogues Clin Neurosci 2016:43:37–46.

[50] Hebert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 1995;14:240–57.

[51] Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980–1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol 1991;20:736–48.

[52] Sharp ES, Gatz M. Relationship between education and dementia: an updated systematic review. Alzheimer Dis Assoc Disord 2011;25:289–304.

[53] Zhang ZY, Liu Z, Deng HH, et al. Effects of acupuncture on vascular dementia (VD) animal models: a systematic review and meta-analysis. BMC Complement Altern Med 2018;18:302.

[54] Hoo JJ, Hoo LL. Review of clinical applications of scalp acupuncture for paralysis: an excerpt from chinese scalp acupuncture. Glob Adv Health Med 2012;1:102–21.

[55] Zhu MJ, Zhang H. Meta-analysis in treating vascular dementia with different acupuncture methods. Liaoning J Tradit Chin Med 2009;36:1475–7.

[56] Wilcock G, Möbius HJ, Stöf...
Zhang TS, Yang L, Hu R, et al. Effect of electroacupuncture on the contents of excitatory amino acids in cerebral tissue at different time courses in rats with cerebral ischemia and reperfusion injury. Acupunct Res 2007;32:234–6.

Zhang CH, Liu JM. Effect of acupuncture at Sishencong (EX-HN 1) on sleeping in the patient of insomnia. Chin Acu-Moxi 2005;25:847–9.

Zhan J, Pan R, Guo Y, et al. Acupuncture at Baihui (GV 20) and Shenting (GV 24) combined with basic treatment and regular rehabilitation for post-stroke cognitive impairments: a randomized controlled trial. Chin Acu-Moxi 2016;36:803–6.

Zhang H, Zhao L, He CQ, et al. Clinically multi-central randomized controlled study on scalp electroacupuncture for treatment of vascular dementia. Chin Acu-Moxi 2008;28:783–7.

Chen CH, Hsieh CL. Effect of acupuncture on oxidative stress induced by cerebral ischemia-reperfusion injury. Antioxidants 2020;9:248.

Yasui K, Baba A. Therapeutic potential of superoxide dismutase (SOD) for resolution of inflammation. Inflamm Res 2006;55:559–63.

Inal ME, Kanbak G, Sunal E. Antioxidant enzyme activities and malondialdehyde levels related to aging. Clin Chim Acta 2001;305:75–80.

Zhang L, Sun L, Liu Y, et al. Effect of Nimodipine treatment on oxygen free radical metabolism of vascular dementia mice when applied at different time points. J Guizhou Med Univ 2017;42:305–7.

Ding K. Clinical research collection on SOD. Beijing, P.R. China: Atomic Energy Press; 1992. 1-12 (in Chinese).

Wang F, Wang M. Acupuncture at five mind points combined with modified kidney qi decoction for vascular dementia of kidney essence deficiency. Chin Acu-Moxi 2018;38:127–31.

Lai XS, Mo FZ, Jiang GH, et al. Observation of clinical effect of acupuncture on vascular dementia and its influence on superoxide dismutase, lipid peroxide and nitric oxide. Chin J Integr Tradit West Med 1998;18:648–51.

Vincent SR. Nitric oxide neurons and neurotransmission. Prog Neurobiol 2010;90:246–55.

Tian H, Zhang Y, Zhang T, et al. Advances in the biological effects of nitric oxide. J Int Neuronal Neurosurg 1995;22:87–9.

Huang X, Zhu K. New progress in basic research of ischemic cerebrovascular disease. Foreign Med Sci: Cerebrovasc Dis 1995;3:3–7. (in Chinese).

Leung MC, Yip KK, Lam CT, et al. Acupuncture improves cognitive function: a systematic review. Neural Regen Res 2013;8:1673–84.

Su X, Wu Z, Mai F, et al. ‘Governor vessel-unblocking and mind-regulating’ acupuncture therapy ameliorates cognitive dysfunction in a rat model of middle cerebral artery occlusion. Int J Mol Med 2019;43:231–32.

Liu CZ, Lei B. Effect of acupuncture intervention on learning-memory ability and cerebral superoxide dismutase activity and malonaldehyde concentration in chronic fatigue syndrome rats. Acupuncture 2013;38:478–81.

Ouyang Q, Li Z, Mu Y, et al. Relationship between promoting effect of acupuncture on learning memory of rats and its anti-oxidation effect. J Nanjing Univ Tradit Chin Med (Nat Sci) 2002;18:110–2.

Mu Y, Li Z, Shen M, et al. Influence of combining acupuncture and medicine on NO and NOS in rats’ hippocampi with acquired learning-memory disturbance and their correlation. Shanghai J Acup Moxib 2003;22:3–5.

Wang L, Tang C, Lai X. Effects of electroacupuncture on learning, memory and formation system of free radicals in brain tissues of vascular dementia model rats. J Tradit Chin Med Sci 2004;24:140–3.